SecBot SecBot
SECBOTREPLAY Home › Report › DRTSW

DRTSW · Alpha Tau announced that an abstract on its Alpha DaRT combination…

Alpha Tau Medical Ltd. · 6-K filed May 5, 2026 at 09:02 ET

At the news

NEUTRALIMPACT 3/10

6-K filed May 5, 2026 at 09:02 ET

Alpha Tau announced that an abstract on its Alpha DaRT combination therapy with pembrolizumab for elderly head and neck cancer patients was accepted for a podium presentation at the AHNS International Conference in July 2026. The filing is a routine clinical milestone update with no new financial data or regulatory approval, and the stock has historically not reacted positively to similar announcements.

  • Abstract on Alpha DaRT + pembrolizumab in elderly HNSCC patients accepted for podium presentation at AHNS 12th International Conference (July 18-22, 2026, Boston).
  • Presentation scheduled for July 21, 2026, during Proffered Papers session on Radiation and Adjuvant Therapies.
  • Study conducted at Hadassah Medical Center, Jerusalem; complete top-line data to be presented.
  • No financial figures, revenue, EPS, or guidance changes reported in the filing.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access